Revenue increased 25.4%
Revenue changed +25.4% from the comparable as-filed period.
$678.0M→$850.5M1 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed +25.4% from the comparable as-filed period.
Net income changed -236.6% from the comparable as-filed period.
Cash & equivalents changed -50.7% from the comparable as-filed period.
Research & development changed +36.8% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.